Copyright Reports & Markets. All rights reserved.

Global Antisense and RNAi Therapeutics Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Antisense and RNAi Therapeutics Drug by Type
    • 1.3.1 Overview: Global Antisense and RNAi Therapeutics Drug Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Antisense and RNAi Therapeutics Drug Consumption Value Market Share by Type in 2025
    • 1.3.3 Antisense Oligonucleotide
    • 1.3.4 Aptamer
    • 1.3.5 Other
  • 1.4 Global Antisense and RNAi Therapeutics Drug Market by Application
    • 1.4.1 Overview: Global Antisense and RNAi Therapeutics Drug Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Neuromuscular Diseases
    • 1.4.3 ATTR
    • 1.4.4 Hepatic VOD
    • 1.4.5 Other
  • 1.5 Global Antisense and RNAi Therapeutics Drug Market Size & Forecast
  • 1.6 Global Antisense and RNAi Therapeutics Drug Market Size and Forecast by Region
    • 1.6.1 Global Antisense and RNAi Therapeutics Drug Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Antisense and RNAi Therapeutics Drug Market Size by Region, (2021-2032)
    • 1.6.3 North America Antisense and RNAi Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Antisense and RNAi Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.6 South America Antisense and RNAi Therapeutics Drug Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Biogen
    • 2.1.1 Biogen Details
    • 2.1.2 Biogen Major Business
    • 2.1.3 Biogen Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.1.4 Biogen Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Biogen Recent Developments and Future Plans
  • 2.2 Sarepta Therapeutics
    • 2.2.1 Sarepta Therapeutics Details
    • 2.2.2 Sarepta Therapeutics Major Business
    • 2.2.3 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.2.4 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sarepta Therapeutics Recent Developments and Future Plans
  • 2.3 Jazz Pharmaceuticals
    • 2.3.1 Jazz Pharmaceuticals Details
    • 2.3.2 Jazz Pharmaceuticals Major Business
    • 2.3.3 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.3.4 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Jazz Pharmaceuticals Recent Developments and Future Plans
  • 2.4 Bausch & Lomb
    • 2.4.1 Bausch & Lomb Details
    • 2.4.2 Bausch & Lomb Major Business
    • 2.4.3 Bausch & Lomb Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.4.4 Bausch & Lomb Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bausch & Lomb Recent Developments and Future Plans
  • 2.5 Alnylam Pharmaceuticals
    • 2.5.1 Alnylam Pharmaceuticals Details
    • 2.5.2 Alnylam Pharmaceuticals Major Business
    • 2.5.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.5.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
  • 2.6 Dynavax Technologies
    • 2.6.1 Dynavax Technologies Details
    • 2.6.2 Dynavax Technologies Major Business
    • 2.6.3 Dynavax Technologies Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.6.4 Dynavax Technologies Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Dynavax Technologies Recent Developments and Future Plans
  • 2.7 Kastle therapeutics
    • 2.7.1 Kastle therapeutics Details
    • 2.7.2 Kastle therapeutics Major Business
    • 2.7.3 Kastle therapeutics Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.7.4 Kastle therapeutics Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Kastle therapeutics Recent Developments and Future Plans
  • 2.8 Akcea Therapeutics
    • 2.8.1 Akcea Therapeutics Details
    • 2.8.2 Akcea Therapeutics Major Business
    • 2.8.3 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product and Solutions
    • 2.8.4 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Akcea Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Antisense and RNAi Therapeutics Drug Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Antisense and RNAi Therapeutics Drug by Company Revenue
    • 3.2.2 Top 3 Antisense and RNAi Therapeutics Drug Players Market Share in 2025
    • 3.2.3 Top 6 Antisense and RNAi Therapeutics Drug Players Market Share in 2025
  • 3.3 Antisense and RNAi Therapeutics Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Antisense and RNAi Therapeutics Drug Market: Region Footprint
    • 3.3.2 Antisense and RNAi Therapeutics Drug Market: Company Product Type Footprint
    • 3.3.3 Antisense and RNAi Therapeutics Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Antisense and RNAi Therapeutics Drug Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Antisense and RNAi Therapeutics Drug Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Antisense and RNAi Therapeutics Drug Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Antisense and RNAi Therapeutics Drug Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Antisense and RNAi Therapeutics Drug Consumption Value by Type (2021-2032)
  • 6.2 North America Antisense and RNAi Therapeutics Drug Market Size by Application (2021-2032)
  • 6.3 North America Antisense and RNAi Therapeutics Drug Market Size by Country
    • 6.3.1 North America Antisense and RNAi Therapeutics Drug Consumption Value by Country (2021-2032)
    • 6.3.2 United States Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Antisense and RNAi Therapeutics Drug Consumption Value by Type (2021-2032)
  • 7.2 Europe Antisense and RNAi Therapeutics Drug Consumption Value by Application (2021-2032)
  • 7.3 Europe Antisense and RNAi Therapeutics Drug Market Size by Country
    • 7.3.1 Europe Antisense and RNAi Therapeutics Drug Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.3 France Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Antisense and RNAi Therapeutics Drug Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Antisense and RNAi Therapeutics Drug Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Antisense and RNAi Therapeutics Drug Market Size by Region
    • 8.3.1 Asia-Pacific Antisense and RNAi Therapeutics Drug Consumption Value by Region (2021-2032)
    • 8.3.2 China Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.5 India Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Antisense and RNAi Therapeutics Drug Consumption Value by Type (2021-2032)
  • 9.2 South America Antisense and RNAi Therapeutics Drug Consumption Value by Application (2021-2032)
  • 9.3 South America Antisense and RNAi Therapeutics Drug Market Size by Country
    • 9.3.1 South America Antisense and RNAi Therapeutics Drug Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Antisense and RNAi Therapeutics Drug Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Antisense and RNAi Therapeutics Drug Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Antisense and RNAi Therapeutics Drug Market Size by Country
    • 10.3.1 Middle East & Africa Antisense and RNAi Therapeutics Drug Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Antisense and RNAi Therapeutics Drug Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Antisense and RNAi Therapeutics Drug Market Drivers
  • 11.2 Antisense and RNAi Therapeutics Drug Market Restraints
  • 11.3 Antisense and RNAi Therapeutics Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Antisense and RNAi Therapeutics Drug Industry Chain
  • 12.2 Antisense and RNAi Therapeutics Drug Upstream Analysis
  • 12.3 Antisense and RNAi Therapeutics Drug Midstream Analysis
  • 12.4 Antisense and RNAi Therapeutics Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Antisense and RNAi Therapeutics Drug market size was valued at US$ 998 million in 2025 and is forecast to a readjusted size of US$ 1503 million by 2032 with a CAGR of 6.1% during review period.
    Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
    This report is a detailed and comprehensive analysis for global Antisense and RNAi Therapeutics Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Antisense and RNAi Therapeutics Drug market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Antisense and RNAi Therapeutics Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Antisense and RNAi Therapeutics Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Antisense and RNAi Therapeutics Drug market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Antisense and RNAi Therapeutics Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Antisense and RNAi Therapeutics Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Antisense and RNAi Therapeutics Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Antisense Oligonucleotide
    Aptamer
    Other
    Market segment by Application
    Neuromuscular Diseases
    ATTR
    Hepatic VOD
    Other
    Market segment by players, this report covers
    Biogen
    Sarepta Therapeutics
    Jazz Pharmaceuticals
    Bausch & Lomb
    Alnylam Pharmaceuticals
    Dynavax Technologies
    Kastle therapeutics
    Akcea Therapeutics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Antisense and RNAi Therapeutics Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Antisense and RNAi Therapeutics Drug, with revenue, gross margin, and global market share of Antisense and RNAi Therapeutics Drug from 2021 to 2026.
    Chapter 3, the Antisense and RNAi Therapeutics Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Antisense and RNAi Therapeutics Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense and RNAi Therapeutics Drug.
    Chapter 13, to describe Antisense and RNAi Therapeutics Drug research findings and conclusion.

    Buy now